Takeda Reports Results of Vedolizumab in P-III Trial for the Prevention of Intestinal aGvHD in Patients Undergoing allo-HSCT
Shots:
- The P-III clinical trial (GRAPHITE) evaluates the safety & efficacy of vedolizumab (300mg) vs PBO, in the ratio 1:1, as prophylaxis of intestinal aGvHD in patients (n=333) who received allo-HSCT as a treatment for a hematologic malignancy or myeloproliferative disorder from an unrelated donor
- The study depicted vedolizumab to achieve a statistically significant improvement in intestinal aGvHD-free survival vs PBO on Day 180 after allo-HSCT whereas along with a significant superiority vs PBO for intestinal aGvHD-free & relapse-free survival by Day +180 & for Grade C-D aGvHD-free survival at Day +180
- Vedolizumab is a humanized mAb developed to antagonize the alpha4beta7 integrin by inhibiting its binding to intestinal MAdCAM-1 expect VCAM-1
Ref: Businesswire | Image: Takeda
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
